HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kratom In Supplements Reaches Dead End On DEA Direct Regulatory Path

This article was originally published in The Rose Sheet

Executive Summary

DEA says more kratom was seized from US firms in the first half of 2016 than in any previous year, but the seizures came two years after FDA imposed an import alert to stop shipments and three years after the agency stumbled out of the gate in determining whether the ingredient could be used in supplements.

You may also be interested in...



Controversy Brews With 'Inaccurate' Reports Linking Kratom To Deaths

American Kratom Association and independent researchers explain the ingredient's history of safe use in a media briefing. Medical examiners "have tried to pin on kratom" the recent deaths of men in Florida and New York, says trade group Chairman Dave Herman.

DEA Takes Comments On Kratom, But Keeps Eye On Scheduling

DEA will accept comments through Dec. 1 on its proposal to move the active materials in kratom into Schedule I under CSA to avoid an imminent hazard to public safety.

Kratom Reprieve From Scheduling Requested By House Members

Members headed by Reps. Mark Pocan, D-WI, and Matt Salmon, R-AZ, say the proposal was made without allowing opportunity for comment by experts, supplement industry stakeholders and consumers.

Related Content

Topics

UsernamePublicRestriction

Register

RS108527

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel